163 related articles for article (PubMed ID: 1321094)
1. Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells.
Friedl P; König B; König W
Immunology; 1992 May; 76(1):86-94. PubMed ID: 1321094
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
4. Modulation of leukotriene generation by invasive bacteria.
Gröne M; Scheffer J; König W
Immunology; 1992 Nov; 77(3):400-7. PubMed ID: 1335960
[TBL] [Abstract][Full Text] [Related]
5. [LTB4-metabolism and histamine liberation by granulocytes in the disease pattern of cystic fibrosis (CF)].
Saak A; Schönfeld W; König W; von der Hardt H
Pneumologie; 1991 Nov; 45(11):913-23. PubMed ID: 1722312
[TBL] [Abstract][Full Text] [Related]
6. Modulation of leukotriene release from human polymorphonuclear leucocytes by PMA and arachidonic acid.
Raulf M; König W
Immunology; 1988 May; 64(1):51-9. PubMed ID: 2838420
[TBL] [Abstract][Full Text] [Related]
7. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.
LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T
Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
9. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
10. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Tümmler B; Bosshammer J; Breitenstein S; Brockhausen I; Gudowius P; Herrmann C; Herrmann S; Heuer T; Kubesch P; Mekus F; Römling U; Schmidt KD; Spangenberg C; Walter S
Behring Inst Mitt; 1997 Feb; (98):249-55. PubMed ID: 9382747
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
Holby N; Olling S
Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
[TBL] [Abstract][Full Text] [Related]
12. Antibody response of rabbits and cystic fibrosis patients to an alginate-specific outer membrane protein of a mucoid strain of Pseudomonas aeruginosa.
Rehm BH; Grabert E; Hein J; Winkler UK
Microb Pathog; 1994 Jan; 16(1):43-51. PubMed ID: 8057826
[TBL] [Abstract][Full Text] [Related]
13. Effect of cations on leukotriene release: requirements for the metabolism of peptido-leukotrienes (leukotrienes C4, D4) by human polymorphonuclear granulocytes.
Raulf M; Stüning M; König W
Immunology; 1986 Jul; 58(3):479-87. PubMed ID: 3733148
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa.
Stiver HG; Zachidniak K; Speert DP
Clin Invest Med; 1988 Aug; 11(4):247-52. PubMed ID: 2971496
[TBL] [Abstract][Full Text] [Related]
15. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
[TBL] [Abstract][Full Text] [Related]
16. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
Meluleni GJ; Grout M; Evans DJ; Pier GB
J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
[TBL] [Abstract][Full Text] [Related]
17. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis.
Kolpen M; Hansen CR; Bjarnsholt T; Moser C; Christensen LD; van Gennip M; Ciofu O; Mandsberg L; Kharazmi A; Döring G; Givskov M; Høiby N; Jensen PØ
Thorax; 2010 Jan; 65(1):57-62. PubMed ID: 19846469
[TBL] [Abstract][Full Text] [Related]
18. Induction of inflammatory mediators from human polymorphonuclear granulocytes and rat mast cells by haemolysin-positive and -negative E. coli strains with different adhesins.
Scheffer J; Vosbeck K; König W
Immunology; 1986 Dec; 59(4):541-8. PubMed ID: 2433215
[TBL] [Abstract][Full Text] [Related]
19. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
20. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
